MA56383A - Analogues de3-(5-méthyl-1,3-thiazol-2-yl)-n-((1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl)benzamide - Google Patents

Analogues de3-(5-méthyl-1,3-thiazol-2-yl)-n-((1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl)benzamide

Info

Publication number
MA56383A
MA56383A MA056383A MA56383A MA56383A MA 56383 A MA56383 A MA 56383A MA 056383 A MA056383 A MA 056383A MA 56383 A MA56383 A MA 56383A MA 56383 A MA56383 A MA 56383A
Authority
MA
Morocco
Prior art keywords
methyl
thiazol
pyrimidin
trifluoro
ethyl
Prior art date
Application number
MA056383A
Other languages
English (en)
Inventor
Oliver Martin Fischer
Ursula Ganzer
Simon Anthony Herbert
Elisabeth Pook
Andrea Rotgeri
Antje Rottmann
Kai Thede
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of MA56383A publication Critical patent/MA56383A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA056383A 2019-06-27 2020-06-25 Analogues de3-(5-méthyl-1,3-thiazol-2-yl)-n-((1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl)benzamide MA56383A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19182797.1A EP3757103A1 (fr) 2019-06-27 2019-06-27 Analogues de 3-(5-méthyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl}benzamide pour le traitement des maladies neurogeniques

Publications (1)

Publication Number Publication Date
MA56383A true MA56383A (fr) 2022-05-04

Family

ID=67105828

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056383A MA56383A (fr) 2019-06-27 2020-06-25 Analogues de3-(5-méthyl-1,3-thiazol-2-yl)-n-((1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl)benzamide

Country Status (19)

Country Link
US (1) US20230013419A1 (fr)
EP (2) EP3757103A1 (fr)
JP (1) JP2022538270A (fr)
KR (1) KR20220027860A (fr)
CN (1) CN114026086A (fr)
AU (1) AU2020303269A1 (fr)
BR (1) BR112021024325A2 (fr)
CA (1) CA3145204A1 (fr)
CL (1) CL2021003455A1 (fr)
CO (1) CO2021017435A2 (fr)
CR (1) CR20210686A (fr)
EC (1) ECSP21088111A (fr)
IL (1) IL289161A (fr)
JO (1) JOP20210338A1 (fr)
MA (1) MA56383A (fr)
MX (1) MX2021015853A (fr)
PE (1) PE20220219A1 (fr)
PH (1) PH12021553202A1 (fr)
WO (1) WO2020260463A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207507B (zh) 2014-12-09 2020-11-06 拜耳公司 1,3-噻唑-2-基取代的苯甲酰胺
AU2021282039A1 (en) * 2020-05-25 2022-12-01 The National Institutes of Pharmaceutical R&D Co., Ltd. Arylformamide compound and preparation method and medical use thereof
CN115884970B (zh) * 2020-09-24 2025-09-23 中国医药研究开发中心有限公司 芳基甲酰胺类化合物及其制备方法和医药用途
AU2021353722B2 (en) * 2020-09-30 2024-01-11 Humanwell Healthcare (Group) Co., Ltd. Benzamide compound and use thereof
CN114591317A (zh) * 2020-12-04 2022-06-07 武汉人福创新药物研发中心有限公司 P2x3抑制剂及其用途
AU2023247631B2 (en) * 2022-03-29 2026-01-22 Humanwell Healthcare (Group) Co., Ltd. P2x3 inhibitor compound, salt thereof, polymorph thereof and use thereof
CN120227337A (zh) * 2023-12-29 2025-07-01 人福医药集团股份公司 一种p2x3受体拮抗剂的固体分散体及其制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528717B (zh) * 2006-11-09 2013-04-24 弗·哈夫曼-拉罗切有限公司 噻唑和*唑-取代的芳基酰胺类化合物
US8501933B2 (en) * 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
JP2011503066A (ja) * 2007-11-08 2011-01-27 サートリス ファーマシューティカルズ， インコーポレイテッド 可溶化チアゾロピリジン誘導体
WO2009110985A2 (fr) * 2008-02-29 2009-09-11 Renovis, Inc. Composés amides, compositions à base de ces composés et leurs utilisations
CN102245586B (zh) * 2008-12-16 2014-07-09 霍夫曼-拉罗奇有限公司 噻二唑取代的芳基酰胺
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US10183937B2 (en) * 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
CN107207507B (zh) 2014-12-09 2020-11-06 拜耳公司 1,3-噻唑-2-基取代的苯甲酰胺
MX2020012202A (es) * 2018-05-15 2021-01-29 Bayer Ag Benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilizacion de fibras nerviosas.
BR112020022340A2 (pt) * 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas

Also Published As

Publication number Publication date
CL2021003455A1 (es) 2022-08-05
MX2021015853A (es) 2022-02-03
EP3990453A1 (fr) 2022-05-04
PE20220219A1 (es) 2022-02-02
BR112021024325A2 (pt) 2022-01-11
WO2020260463A1 (fr) 2020-12-30
AU2020303269A1 (en) 2022-02-03
CO2021017435A2 (es) 2022-01-17
JP2022538270A (ja) 2022-09-01
PH12021553202A1 (en) 2022-10-24
US20230013419A1 (en) 2023-01-19
KR20220027860A (ko) 2022-03-08
CN114026086A (zh) 2022-02-08
ECSP21088111A (es) 2022-01-31
JOP20210338A1 (ar) 2023-01-30
CR20210686A (es) 2022-02-09
IL289161A (en) 2022-02-01
EP3757103A1 (fr) 2020-12-30
CA3145204A1 (fr) 2020-12-30

Similar Documents

Publication Publication Date Title
MA56383A (fr) Analogues de3-(5-méthyl-1,3-thiazol-2-yl)-n-((1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl)benzamide
IL287030A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy
CY2024024I1 (el) Υδροχλωρικα αλατα ν-(κυανομεθυλ)-4-(2-(4- μορφολινοφαινυλαμινο)πυριμιδιν-4-υλ)βενζαμιδιου
NO2022023I1 (no) Ponesimod (IUPAC name: (R)-5-[3-chloro-4-(2,3-dih ydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolylthiazolidin-4-one) and harmaceutically acceptable salts thereof
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
SI3713919T1 (sl) Kristalinične oblike n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil) fenil)kinolin-8-sulfonamida
EP3994510A4 (fr) Améliorations de latence de suivi de l'oeil
EP4000451C0 (fr) Masque cosmétique pour les yeux
PE20220253A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
PL3999180T3 (pl) Polimorfy (r)-n-(5-(5-etylo-1,2,4-oksadiazol-3-ilo)-2,3-dihydro-1h-inden-1-ylo)-1-metylo-1h-pirazolo-4-karboksyamidu
IL260403B (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
PH12017501060A1 (en) Pharmaceutical combination comprising a selective s1p1 receptor agonist
PL3464276T3 (pl) Nowa postać krystaliczna n-[5-(3,5-difluoro-benzylo)-1h-indazol-3-ilo)-4-(4-metylopiperazyn-1-ylo)-2-tetrahydropiran-4-yloamino)-benzamidu
DK3303323T3 (da) Heterocykliske forbindelser af 3,3-difluorpiperidincarbamat som NR2B-NMDA-receptorantagonister
CO2018001383A2 (es) Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp”
DK3507287T3 (da) Substituerede N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamid og N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamidderivater P2X7 receptorantagonister
IL254943B (en) -(4-(4-(((3r,5r)-5-((1h-4,2,1-triazol-1-yl)methyl)-5-(4,2-difluorophenyl)tetrahydrofuran-3-yl (Methoxy)-3-methylphenyl)piperazin-1-yl)-n-(2-hydroxycyclohexyl)benzamide antifungal or a pharmaceutically acceptable salt thereof
EA201891844A1 (ru) Продукт для ухода за полостью рта
BR112018013364A2 (pt) forma cristalina e composição farmacêutica
DK3309150T3 (da) (r)-3-(4'-(2-(2-methylpyrrolidin-1-yl)ethyl)biphenyl-4-yl)propansyre som histamin-h3-receptormodulatorer til behandlingen af kognitive lidelser
BR112022010019A2 (pt) Processos para preparar 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
DK3827814T3 (da) Ofthalmiske formuleringer
IT201900024036A1 (it) Componente per calzatura
HUE057167T4 (hu) Eljárás 4-(4-aminofenil)morfolin-3-on elõállítására
BR112018013356A2 (pt) sal de cloridrato, formas cristalinas de um sal de cloridrato e composição farmacêutica